Skip to content
Wednesday, March 29, 2023
Latest:
  • SQI Diagnostics Submits RALI-Dx(TM) IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization
  • Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors
  • Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
  • PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin
  • MindMed Announces Inclusion in FTSE Russell Indexes
Biotech Stock Market News

Biotech Stock Market News

Know First, Act First

  • Cannabis & Cancer
  • General
  • Coronavirus
  • Financing & Fiscal
  • Shareholders

BIOTCHNO

BIOTCHNO General 

SQI Diagnostics Submits RALI-Dx(TM) IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization

May 24, 2021June 7, 2021 Raza

Canada NewsWire Test Designed to Assist in Identifying Severe Inflammatory Response in Patients with Confirmed COVID-19 Illness TORONTO , April

Read more
BIOTCHNO Featured 

Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors

April 1, 2021August 4, 2021 RJ

Canada NewsWire HAMILTON , ON and BOSTON , April 1, 2021 /CNW/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company

Read more
BIOTCHNO Cannabis & Cancer 

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

March 31, 2021July 19, 2021 Raza

TOKYO, Mar 31, 2021 – (JCN Newswire) – Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co.,

Read more
BIOTCHNO Trending 

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

March 23, 2021April 20, 2021 Raza

  Canada NewsWire OXFORD, Ohio and COCONUT CREEK, Fla. , March 23, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB)

Read more
BIOTCHNO General 

MindMed Announces Inclusion in FTSE Russell Indexes

March 22, 2021July 26, 2021 Raza

Canada NewsWire NEW YORK , March 22, 2021 /CNW/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic

Read more
BIOTCHNO Financing & Fiscal 

Willow Biosciences Provides Update on Acceleration of Expiry Date of Outstanding Warrants Issued Pursuant to October 2020 Unit Financing

March 3, 2021June 2, 2021 Raza

Canada NewsWire VANCOUVER, BC , March 3, 2021 /CNW/ – Willow Biosciences Inc. (” Willow ” or the ” Company “) (TSX: WLLW)

Read more
BIOTCHNO Shareholders 

ESSA Pharma to Present at Upcoming March Investor Conferences

February 25, 2021May 17, 2021 Raza

Canada NewsWire HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /CNW/ – ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a

Read more
BIOTCHNO Cannabis & Cancer 

The Valens Company Expands Cannabis 2.0 & 3.0

February 25, 2021April 20, 2021 Bachittar

The Valens Company Expands Cannabis 2.0 & 3.0 Footprint with the Acquisition of Leading Canadian Edibles Manufacturer LYF Food Technologies

Read more
BIOTCHNO Financing & Fiscal 

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company

February 19, 2021April 30, 2021 Bachittar

Canada NewsWire Acquisition will help build a full stack digital mental health platform for psychedelic medicines; Ex-Pfizer Digital Medicine Executive

Read more
BIOTCHNO Financing & Fiscal 

SQI Diagnostics Announces New Corporate Website

February 18, 2021April 30, 2021 Bachittar

Canada NewsWire New Website Provides Essential Information on Company’s Strategic Initiative TORONTO,Feb. 18, 2021/CNW/ – SQI Diagnostics Inc. (the “Company”

Read more
  • ← Previous

Cannabis

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
BIOTCHNO Cannabis & Cancer 

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

March 31, 2021July 19, 2021 Raza

TOKYO, Mar 31, 2021 – (JCN Newswire) – Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co.,

The Valens Company Expands Cannabis 2.0 & 3.0
BIOTCHNO Cannabis & Cancer 

The Valens Company Expands Cannabis 2.0 & 3.0

February 25, 2021April 20, 2021 Bachittar
PAOG Announces CBD Nutraceuticals Expansion Plan Multimedia Presentation
BIOTCHNO Cannabis & Cancer 

PAOG Announces CBD Nutraceuticals Expansion Plan Multimedia Presentation

February 16, 2021April 30, 2021 Bachittar
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
BIOTCHNO Cannabis & Cancer 

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

February 11, 2021April 30, 2021 Bachittar
  • Disclaimer
  • Privacy Policy
TD Media LLC dba Life Water Media
5826 New Territory Blvd. Unit #2144 Sugar Land, TX 77479